Rese-cel data presented at multiple medical meetings demonstrated potentially transformative, drug-free clinical responses with a favorable safety profile for autoimmune patients supporting outpatient...
PHILADELPHIA, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies...
– All myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who met key registrational inclusion criteria exceeded the registrational primary endpoint, demonstrating major TIS responses...
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cabaletta Bio (CABA – Research Report) and Icon (ICLR – Research Report) with bullish sentiments.Elevate...
– Gavel brings highly relevant CAR T experience from Legend Biotech where he led the launch and commercialization of CARVYKTI® from 2018 until 2025 – PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE)...
Cantor Fitzgerald analyst Joshua Schimmer reiterated a Buy rating on Cabaletta Bio today and set a price target of $15.00. The company’s shares opened today at $3.15.Elevate Your Investing Strategy:...
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Silence Therapeutics (SLN – Research Report) and Cabaletta Bio (CABA – Research Report) with bullish...
In a report released today, Sami Corwin from William Blair maintained a Buy rating on Cabaletta Bio. The company’s shares closed yesterday at $2.85.Elevate Your Investing Strategy: Take advantage of...
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Cabaletta...
– Complete B cell depletion, rapid reduction in autoantibodies and near-complete resolution of clinical symptoms in two of three refractory patients; all three patients remained off immunomodulators...